Aim: Irinotecan-induced severe toxicities are possibly related to UGT1A1*6 and *28 genotypes. However, the correlation between UGT1A1 polymorphisms and the risk of toxicities induced by low-dose irinotecan plus platinum combination therapy still remains controversial. This prospective observational study aimed to examine the correlation between UGT1A1 genotypes and clinical outcomes of low-dose irinotecan (median 60 mg/m(2) , range 25-115 mg/m(2) ) plus platinum in Japanese patients with solid tumors.
Methods: Toxicity profiles were compared between UGT1A1 SNP heterozygotes (hetero-group) and patients with homozygous SNP profile (*6/*6, *28/*28 and *6/*28). Logistic regression models were used to identify independent risk factors for these toxicities.
Results: A total of 331 patients were enrolled: 84% with hetero-group and 16% with homo-group. Although the initial irinotecan dose was similar, the dose intensities during the three cycles were significantly lower in the homo-group (P < 0.01). Grade 3/4 hematological toxicities were significantly more frequent in the homo-group. Multivariable analysis identified UGT1A1 genotype (P < 0.01) as an independent factor for grade 4 hematological toxicity in the first treatment cycle.
Conclusion: UGT1A1 genotype has a major impact on the increased risk of severe hematological toxicities, even in low-dose irinotecan regimens. UGT1A1 genotypes are useful biomarkers for predicting severe hematological toxicities in patients treated with irinotecan plus platinum analog.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajco.12453 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer.
J Gastrointest Cancer
November 2024
Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China.
Background: The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world study, we were aimed to evaluate which choice will affect the survival of mCRC patients after standard treatment in Chinese patients.
Methods: A total of 129 patients with refractory mCRC were involved in the study.
Bicentric lesion of colon cancer with postoperative fever: A case report.
Oncol Lett
October 2024
Anorectal Department, Yinchuan Traditional Chinese Medicine Hospital, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750001, P.R. China.
Colon adenocarcinoma (COAD) is a malignant tumor type. Fever is the most common postoperative complication of COAD. The present study described the treatment of a patient with early-stage COAD with precancerous colon polyps and the possible cause of postoperative fever.
View Article and Find Full Text PDFAKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation.
Cancer Chemother Pharmacol
September 2024
Department of Gastroenterology, Qixia City People's Hospital, Qixia, Shandong, China.
Purpose: Colorectal cancer (CRC) remains a major global health concern, necessitating innovative therapeutic strategies to enhance treatment efficacy. In this study, we investigated the role of AKR1C4 in CRC and its impact on chemotherapy response.
Methods: AKR1C4 stable knockout CRC cell lines were generated using CRISPR/Cas9 technology.
Banxia Xiexin decoction combined with 5-ASA protects against CPT-11-induced intestinal dysfunction in rats via inhibiting TLR4/NF-κB signaling pathway.
Immun Inflamm Dis
June 2024
Department of Gastroenterology, Xiaoshan Hospital of Traditional Chinese Medicine, Hangzhou, China.
Background: Banxia Xiexin decoction (BXD) can control irinotecan (CPT-11)-caused delayed diarrhea, but the corresponding mechanism remains undefined.
Aims: This paper aimed to uncover the mechanism of BXD in regulating CPT-11-caused delayed diarrhea.
Materials & Methods: Sprague-Dawley (SD) rats were assigned into the control, model, BXD low-dose (BXD-L, 5 g/kg), BXD medium-dose (BXD-M, 10 g/kg), BXD high-dose (BXD-H, 15 g/kg), 5-aminosalicylic acid (5-ASA, 10 mL/kg), and BXD-M + 5-ASA groups.
A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy.
J Cancer Res Clin Oncol
May 2024
Department of Medical Oncology, Ordos Central Hospital, 23th Yijinhuoluo Western Road, Dongsheng District, Ordos, 017000, China.
Objective: The aim of this study is to assess the clinical efficacy of a 5 mg dosage of olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) among female patients diagnosed with gastrointestinal tract tumors.
Methods: Patients undergoing the oxaliplatin/irinotecan chemotherapy regimen were enrolled in this prospective controlled study. The olanzapine group received a 5 mg dosage of olanzapine along with palonosetron and dexamethasone, while the control group received a standard two-combination regimen consisting of dexamethasone and palonosetron.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!